A practical, budget-conscious walkthrough of WIPO ST.26 requirements, from first provisional to PCT and national filings

1. Why Sequence Listings Matter to Early-Stage Ventures

For a biotech venture, the patent portfolio is often the main asset on the balance sheet. Investors, licensing partners and acquirers will review it closely. A sequence listing that is missing, malformed, or inconsistent with the specification can result in an incomplete application, requests for correction and doubts about the quality of the filing.

Pre-revenue and crowdfunded companies face particular constraints. Budgets are limited, the team may be small and scientific rather than legal and the company may be communicating publicly about its technology to attract backers. This guide explains what the sequence listing requirement is, how to prepare one at low cost and how to avoid the mistakes most common in early filings.

Scope note. This guide focuses on U.S. practice and the international standard used by the PCT and many national offices. Requirements differ in detail by jurisdiction, so confirm with your patent attorney and the current rules of each office before filing.

2. The Legal and Technical Framework

What triggers the requirement

The standard requires listing sequences that are “disclosed” in the application, meaning described in the specification, claims, drawings, or elsewhere, if they meet defined thresholds:

Sequence typeThreshold (summary)Notes
Nucleotide sequences10 or more specifically defined nucleotidesDNA and RNA, including modified bases that are annotated according to the standard
Amino acid sequences4 or more specifically defined amino acidsIncludes D-amino acids and modified residues with annotation and peptides with some non-natural elements
Branched or looped sequencesGenerally outside the scope, or handled with special rulesCheck the standard’s treatment of the specific structure
Sequences in figures and tablesIncluded if they meet the thresholdsA sequence shown only as an image still counts as disclosed

These thresholds are summarised and the full definitions of “specifically defined” nucleotides and amino acids and of sequences that are excluded, are in the standard and the USPTO’s guidance. When in doubt, include the sequence.

Provisional applications

A provisional application is not examined and usually does not require a compliant sequence listing at filing, although practice should be confirmed with the current USPTO rules. Even so, including the sequences clearly in the text and preferably in a draft ST.26 file, is useful: it ensures that the written description supports later claims and it lets you build the non-provisional listing from a clean starting point. Remember that only what is disclosed in the provisional can support the priority claim.

3. Public Disclosure Risk for Crowdfunded Ventures

A crowdfunding campaign, investor deck, preprint, conference poster, or social-media post that discloses a sequence can be a public disclosure that affects patentability.

Recommended sequence of events: (1) file at least a well-supported provisional application that includes all key sequences; (2) then publish campaign materials; (3) use general descriptions of the technology without sequences or critical details; (4) put detailed data in a confidential data room under non-disclosure agreements.

4. Preparing a Sequence Listing, Step by Step

4.1 Identify every sequence

  1. Search the specification, claims, drawings, tables, examples and any sequence data appendices for sequences that meet the thresholds.
  2. Assign a stable internal ID to each, then map it to its future SEQ ID NO.
  3. Check that the same sequence is not listed twice under different names and that sequences in figures match those in the text.
  4. Decide on the order of the SEQ ID NOs. Many drafters follow the order of first appearance in the specification, which makes cross-checking easier.

4.2 Create the XML file with the WIPO Sequence tool

WIPO offers a free desktop application, WIPO Sequence, for creating and validating ST.26 listings. It lets users enter or import sequences, add feature annotations and run the same validation checks that offices use. Commercial software and patent-attorney services also exist and may be useful when the portfolio is large or the sequences include many modifications. A typical workflow is:

  1. Start a new sequence listing project and enter the general information: applicant name, invention title, the applicant’s file reference and earliest priority information where applicable.
  2. Add each sequence. For nucleotide sequences, indicate whether DNA or RNA and for amino acid sequences, enter using the standard one-letter or three-letter codes allowed by the tool.
  3. Mark organism information and annotate features, including modified residues, variants and artificial sequences, as required by the standard.
  4. Assign each sequence its SEQ ID NO and keep these consistent with the specification and claims.
  5. Run the validator and fix every error and warning. Warnings may not prevent filing, but should be understood.
  6. Generate the XML file and keep a copy of the project file for future edits.

4.3 Annotate carefully

Annotation is where most mistakes happen. Features such as modified bases, non-standard amino acids, signal peptides, binding sites, or variants must be described with the controlled terms (feature keys and qualifiers) the standard specifies. Key points:

4.4 Align the text, claims and listing

4.5 File correctly

5. Budget-Conscious Tips

Cost areaLow-cost approachWatch out for
Drafting and annotationUse the free WIPO Sequence tool and assign one team member to learn it wellTime spent by scientists on annotation rules; do not skip the validator
Attorney reviewPrepare a clean spreadsheet of sequences, names, sources and modifications before engaging counselDisorganised inputs raise billable time and the risk of mistakes
Conversion from older formatsUse the conversion features in the tool, then review manuallyAutomatic conversion may mis-handle modified residues and ambiguous positions
Corrections after filingValidate before filing and cross-check against the text twiceNotices to comply may bring deadlines, fees and extra attorney time
Foreign filingsUse one ST.26 file for PCT and national phases where acceptedLocal formal requirements and translation of descriptive text
Provisional stageInclude all sequences in the text and keep a draft listingDo not defer sequence data to later, since provisional support is limited to what is disclosed

6. Common Errors and How to Avoid Them

ErrorConsequencePrevention
Sequence disclosed in text or figure but omitted from the listingNotice requiring a corrected listing; risk of questions about completenessSearch the whole application for sequences before finalising
SEQ ID NO. mismatch between the listing, description and claimsConfusion in examination; possible indefinitenessBuild a cross-reference table and verify it
Using an outdated ST.25 fileRejection of the file by the Office’s systemCreate all new listings in ST.26 from the start
Incorrect annotation of modified residuesValidation errors, or a listing that does not accurately describe the moleculeLearn the controlled vocabulary; review with a bioinformatics specialist
Adding sequences not in the original applicationNew-matter issues; a listing cannot cure a lack of disclosureCompare the final listing against the application as filed
Sequences too short or not “specifically defined” included or excluded in errorUnnecessary entries or omissionsApply the thresholds carefully and consult the standard
Inconsistent organism or origin descriptionsConfusing records for examiners and later due diligenceStandardise how the source and artificial origin are described
No archived project fileHeavy rework for later filingsArchive the project file with each filing

7. Beyond Filing: Using Sequences Strategically

8. Pre-Filing Checklist

 Item
☐A provisional application including all key sequences is filed before any public disclosure.
☐Every sequence meeting the thresholds is identified from the specification, claims, drawings and tables.
☐The listing is built as an ST.26 XML file, using the WIPO Sequence tool or equivalent.
☐Validator run with all errors resolved and warnings reviewed.
☐Annotations for modified residues, variants and artificial sequences are checked.
☐SEQ ID NOs are used consistently in the text, claims and listing.
☐No sequence is in the listing that is not disclosed in the application.
☐The file is submitted in the correct document category through Patent Center, or through the PCT receiving office.
☐Project file, spreadsheet and filing evidence are archived.
☐Crowdfunding and investor materials reviewed to avoid premature disclosure of sequences.

9. Conclusion

The sequence listing is a small part of a biotech patent application, but it is a technical requirement that can cause outsized trouble if handled late or carelessly. For pre-revenue and crowdfunded ventures, the winning approach is straightforward: file early, keep sequence data organised, use the free ST.26 tools, validate before filing and manage public disclosures with care. Doing so protects the company’s most important intangible assets, avoids avoidable costs and presents a clean record to the investors and partners who will inspect it.

This article is provided for general informational purposes and is not legal advice. Statutes, rules, fee schedules and USPTO practice change; confirm current requirements and consult a registered patent practitioner or trademark attorney before relying on any point here.

Leave a Reply

Your email address will not be published. Required fields are marked *